Orion Corporation: Managers’ transactions – Veli-Matti Mattila

    Orion Corporation: Managers’ transactions – Veli-Matti Mattila 

ORION CORPORATION MANAGERS’ TRANSACTIONS 22 APRIL 2024 at 9.45 EEST        

Orion Corporation: Managers’ transactions – Veli-Matti Mattila

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Veli-Matti MattilaPosition: Member of the Board/Deputy member Issuer: Orion OyjLEI: 74370029VAHCXDR7B745Notification type: INITIAL NOTIFICATIONReference number: 59158/6/8

____________________________________________Transaction date: 2024-04-19Outside a trading venueInstrument type: SHAREISIN: FI0009014369Nature of transaction: GIFT,DONATION OR INHERITANCE (RECEIVED)

Transaction details(1): Volume: 460 Unit price: 0 EUR

Aggregated transactions (1): Volume: 460 Volume weighted average price: 0 EUR____________________________________________Transaction date: 2024-04-19Outside a trading venueInstrument type: SHAREISIN: FI0009014377Nature of transaction: GIFT,DONATION OR INHERITANCE (RECEIVED)

Transaction details(1): Volume: 386 Unit price: 0 EUR

Aggregated transactions (1): Volume: 386 Volume weighted average price: 0 EUR

Orion Corporation

Liisa HurmePresident and CEO

Olli HuotariSVP, Corporate Functions

                                                

Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandhttp://www.orion.fi/enhttp://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.